Presentation is loading. Please wait.

Presentation is loading. Please wait.

Lopinavir-ritonavir mg BID (n = 354)

Published byBarry Fitzgerald Modified over 6 years ago

Similar presentations

Presentation on theme: "Lopinavir-ritonavir mg BID (n = 354)"— Presentation transcript:

1 Switching from Lopinavir-Ritonavir to Raltegravir SWITCHMRK 1 & 2 Trials

2 Lopinavir-ritonavir 400-100mg BID (n = 354)
Switching from Lopinavir-Ritonavir to Raltegravir SWITCHMRK 1 & 2 Trials: Study Design Study Design: SWITCHMRK 1&2 Background: Randomized, double-blind, double-dummy trial evaluating switch from lopinavir-ritonavir to raltegravir in combination with background therapy Inclusion Criteria (n = 707 combined) - Age > HIV RNA < 50 copies/mL for >3 months - On lopinavir-ritonavir - CD4 count >100 cells/mm3 - No lipid-lowering agent for 12 weeks Treatment Arms* - Raltegravir 400 mg BID + background therapy - Lopinavir-ritonavir mg BID + background therapy Switch Arm Raltegravir 400 mg BID (n = 353) Continuation Arm Lopinavir-ritonavir mg BID (n = 354) *Background therapy in both groups included at least 2 NRTIs Source: Eron JJ, et al. Lancet ;375:

3 Switching from Lopinavir-Ritonavir to Raltegravir SWITCHMRK 1 & 2 Trials: Results
Week 24: Virologic Response (Non-Completion Counted as Failure) 139/172 152174 154/175 167/178 293/347 319/352 Virologic Failure: Lopinavir-Ritonavir (N = 4); Raltegravir (N = 12) Source: Eron JJ, et al. Lancet ;375:

4 Switching from Lopinavir-Ritonavir to Raltegravir SWITCHMRK 1 Trial: Results
SWITCHMRK 1 Week 12: Analysis of Lipids Source: Eron JJ, et al. Lancet ;375:

5 Switching from Lopinavir-Ritonavir to Raltegravir SWITCHMRK 2 Trial: Results
SWITCHMRK 2 Week 12: Analysis of Lipids Source: Eron JJ, et al. Lancet ;375:

6 Switching from Lopinavir-Ritonavir to Raltegravir SWITCHMRK 1 & 2 Trials: Conclusions
Interpretation: “Although switching to raltegravir was associated with greater reductions in serum lipid concentrations than was continuation of lopinavir-ritonavir, efficacy results did not establish non-inferiority of raltegravir to lopinavir-ritonavir.” Source: Eron JJ, et al. Lancet ;375:

7

Download ppt "Lopinavir-ritonavir mg BID (n = 354)"

Similar presentations

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.
Switch to RAL-containing regimen - Canadian Study - CHEER - Montreal Study - EASIER - SWITCHMRK - SPIRAL.

Switch to RAL-containing regimen - Canadian Study - CHEER - Montreal Study - EASIER - SWITCHMRK - SPIRAL.
Switch to ATV/r monotherapy - ATARITMO - Swedish Study - ACTG A5201 - OREY.

Switch to ATV/r monotherapy - ATARITMO - Swedish Study - ACTG A OREY.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.

Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:

Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:
Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.

Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.
Switch to LPV/r monotherapy  Pilot LPV/r  M03-613  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.

Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
Comparison of INSTI vs INSTI  QDMRK  SPRING-2. Eron JJ, Lancet Infect Dis 2011;11:907-15 QDMRK  Design  Objective –Non inferiority of RAL QD: % HIV.

Comparison of INSTI vs INSTI  QDMRK  SPRING-2. Eron JJ, Lancet Infect Dis 2011;11: QDMRK  Design  Objective –Non inferiority of RAL QD: % HIV.
Switch to LPV/r monotherapy  Pilot LPV/r  M03-613  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
02-15 INFC-1022464-0001 Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:

02-15 INFC Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study* 1 Date of preparation:
Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.

Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.

POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.

Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.

ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
KLEAN Study: Fosamprenavir/Ritonavir Associated With Similar Efficacy and Safety as Lopinavir/Ritonavir SGC in Treatment- Naive Patients Slideset on: Eron.

KLEAN Study: Fosamprenavir/Ritonavir Associated With Similar Efficacy and Safety as Lopinavir/Ritonavir SGC in Treatment- Naive Patients Slideset on: Eron.
Tipranavir/Ritonavir Superior to Comparator PI/Ritonavir at Week 48 in Multiclass-Experienced Patients Slideset on: Hicks CB, Cahn P, Cooper DA, et al.

Tipranavir/Ritonavir Superior to Comparator PI/Ritonavir at Week 48 in Multiclass-Experienced Patients Slideset on: Hicks CB, Cahn P, Cooper DA, et al.
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

Similar presentations

Ads by Google